How do you adjust transplant-benefit–based decision-making for HCC patients with prior immune checkpoint inhibitor exposure, given the potential for increased peri-transplant rejection or graft loss?

Some programs aim not to proceed with transplantation (LT) for 1 month subsequent to the administration of immunotherapy in order to avoid rejection. However, this is not often feasible, and the reality is that the half-life of these medications can be closer to 50-60 days. My personal opinion is th...